MAIA reports 30-month (912-day) survival for a Phase 2 NSCLC patient; ESMO posters presented

MAIA Biotechnology, Inc.

One third-line NSCLC patient on ateganosine (THIO) survived 30 months/912 days as of Sep 17, 2025.
THIO-101 Phase 2 trial evaluates ateganosine + cemiplimab in checkpoint-inhibitor-resistant advanced NSCLC.
New Phase 3 THIO-104 trial compares ateganosine+ICI vs chemotherapy in ICI-resistant NSCLC.
Posters presented at ESMO 2025 in Berlin; full posters available on MAIA website.
CEO states >2-year survival is a clear signal of ateganosine's efficacy in eliminating NSCLC tumors.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.